BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Remimazolam readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Remimazolam\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07925684-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Remimazolam: Phase na readout est. (NCT07925684)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Determination of ED90 of Remima
 zolam Besylate Combined With Alfentanil for Gastroscopy Sedation in Obese 
 Patients\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07925684
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718152-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07718152)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Ciprofol and Remimazolam for Int
 raoperative Neurophysiological Monitoring During Spine Surgery\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07718152
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748884-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07748884)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Comparing Esketamine and Remazol
 am With Propofol for Breathing Safety in Pediatric Gastroscopy\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07748884
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395596-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07395596)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam for Bronchoscopy in 
 High-Risk Patients\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07395596
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891145-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase na readout est. (NCT05891145)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam for Postoperative A
 trial Fibrillation\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05891145
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700681-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase na readout est. (NCT06700681)
DESCRIPTION:Remimazolam\, phase na.\nStudy: RCT Comparing Remimazolam With 
 Propofol Under EEG DSA Guidance During Cardiac Electrophysiology Studies a
 nd Ablation\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06700681
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311642-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Remimazolam: Phase na readout est. (NCT07311642)
DESCRIPTION:Remimazolam\, phase na.\nStudy: The Effect of Intraoperative Bi
 naural Beats on Remimazolam Dose Required for Maintenance of General Anest
 hesia\nEstimated primary completion: 1 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07311642
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351474-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Remimazolam: Phase na readout est. (NCT07351474)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam for Reducing Postop
 erative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy\n
 Estimated primary completion: 25 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07351474
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06777758-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT06777758)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Comparison of Remimazolam and Pr
 opofol in Endoscopic Examinations and Treatments\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/remimazolam#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06777758
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496165-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase na readout est. (NCT06496165)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam Besylate and Propof
 ol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06496165
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377695-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remimazolam: Phase na readout est. (NCT07377695)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam Consumption: TCI vs
 . Manual Infusion\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07377695
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046364-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07046364)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam and Emergence Deliri
 um in Pediatrics\nEstimated primary completion: 1 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07046364
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213544-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07213544)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam vs Propofol in Laser
  Burn Cases\nEstimated primary completion: 1 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07213544
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596589-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Remimazolam: Phase 3 readout est. (NCT07596589)
DESCRIPTION:Remimazolam\, phase 3.\nStudy: Effect of Remimazolam Sedation o
 n Outcomes of Mechanically Ventilated Patients in the ICU\nEstimated prima
 ry completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07596589
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740343-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Remimazolam: Phase na readout est. (NCT07740343)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam for Postoperative S
 leep in Elderly Patients\nEstimated primary completion: 31 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07740343
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620782-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Remimazolam: Phase na readout est. (NCT07620782)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Response Surface Modeling of Re
 mimazolam and Sevoflurane\nEstimated primary completion: 1 April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07620782
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661810-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Remimazolam: Phase na readout est. (NCT07661810)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Patient-controlled Remimazolam 
 Sedation Under Spinal Anesthesia\nEstimated primary completion: 30 April 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07661810
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674719-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270626
DTEND;VALUE=DATE:20270627
SUMMARY:Remimazolam: Phase na readout est. (NCT07674719)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam on the Incidence of
  Postoperative Acute Kidney Injury\nEstimated primary completion: 26 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0767471
 9
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155265-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Remimazolam: Phase 3 readout est. (NCT07155265)
DESCRIPTION:Remimazolam\, phase 3.\nStudy: REMIMID-ICU: Remimazolam vs Mida
 zolam for Deep Sedation in Hemodynamically Unstable\, Mechanically Ventila
 ted Adults\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07155265
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854197-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Remimazolam: Phase na readout est. (NCT07854197)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Effect of Remimazolam on Hypoxe
 mia and/or Hypotension in Prostate Biopsy\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazo
 lam#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07854197
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789275-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07789275)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam Versus Propofol for 
 Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Veno
 us Pressure\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07789275
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740655-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07740655)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Low-dose Versus Standard-dose Re
 mimazolam for Prevention of Emergence Agitation After Nasal Surgery\nEstim
 ated primary completion: 31 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07740655
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717684-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07717684)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Time to Loss of Consciousness Wi
 th Remimazolam Versus Propofol for Anesthetic Induction in Laparoscopic Ch
 olecystectomy\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07717684
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459322-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:Remimazolam: Phase na readout est. (NCT07459322)
DESCRIPTION:Remimazolam\, phase na.\nStudy: The Use of Remimazolam Versus D
 exmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy\nEstima
 ted primary completion: 5 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07459322
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265128-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07265128)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam vs Midazolam to Redu
 ce Delirium in Adults ≥65 Undergoing CPB Valve Surgery\nEstimated primar
 y completion: September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07265128
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829458-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07829458)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: The Use of Remimazolam for TEE\n
 Estimated primary completion: September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07829458
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806006-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07806006)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Effect of Remimazolam Versus Pro
 pofol Total Intravenous Anesthesia on Intraoperative Hemodynamic Stability
  in Patients Undergoing Thoracic or Abdominal Endovascular Aortic Repair\n
 Estimated primary completion: 15 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07806006
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04851717-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Remimazolam: Phase 2/3 readout est. (NCT04851717)
DESCRIPTION:Remimazolam\, phase 2/3.\nStudy: Investigation of Remimazolam i
 n Children Undergoing Sedation for Medical Procedures\nEstimated primary c
 ompletion: October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remimazolam#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04851717
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277881-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07277881)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: The Effect of Reversal of Remima
 zolam Sedation With Flumazenil on Cognitive Function in Patients Undergoin
 g Hip Arthroplasty Under Spinal Anesthesia\nEstimated primary completion: 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remimaz
 olam#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07277881
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863063-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07863063)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam Concentration and Se
 dation Depth During Lower Extremity Surgery Under Spinal Anesthesia\nEstim
 ated primary completion: October 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07863063
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251101-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Remimazolam: Phase na readout est. (NCT07251101)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Hemodynamic Effects of Remimazo
 lam vs Propofol During Robot-assisted Gynecologic Surgery\nEstimated prima
 ry completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07251101
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816068-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07816068)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Effects of Remimazolam on Postop
 erative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients
  Undergoing Aortic Arch Surgery\nEstimated primary completion: 1 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781606
 8
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456111-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07456111)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: A Comparison of Remimazolam Besy
 late and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy
 \nEstimated primary completion: 30 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07456111
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05160987-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Remimazolam: Phase na readout est. (NCT05160987)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Effect of Remimazolam With Prot
 ocolized Sedation on Critical Ill\, Mechanical Ventilated Patients Compare
 d With Midazolam\nEstimated primary completion: 30 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05160987
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927582-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Remimazolam: Phase na readout est. (NCT07927582)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Pulsed Field Ablation for Atria
 l Fibrillation Under General Anesthesia Versus Remimazolam-based Deep Seda
 tion\nEstimated primary completion: 30 November 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07927582
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290205-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Remimazolam: Phase 1 readout est. (NCT07290205)
DESCRIPTION:Remimazolam\, phase 1.\nStudy: Remimazolam NeuroImaging\nEstima
 ted primary completion: 1 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07290205
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908121-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Remimazolam: Phase na readout est. (NCT07908121)
DESCRIPTION:Remimazolam\, phase na.\nStudy: The Effect of Remimazolam Tosyl
 ate on the Incidence of Postoperative Delirium in Older Patients Undergoin
 g Cardiac Surgery: A Prospective Randomized Controlled Trial\nEstimated pr
 imary completion: 23 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07908121
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05728775-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Remimazolam: Phase 4 readout est. (NCT05728775)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: REmimazolam vs Propofol Total In
 travenous Anesthesia on Outcomes After Major Noncardiac SurgEry\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05728775
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787364-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Remimazolam: Phase na readout est. (NCT07787364)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Intraoperative Targeted Versus 
 Liberal Blood Pressure Management in Patients Undergoing Off-pump Coronary
  Artery Bypass Grafting\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07787364
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265050-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Remimazolam: Phase na readout est. (NCT07265050)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Comparison of Emergence Agitati
 on Between Remimazolam With Flumazenil and Propofol-based Total Intravenou
 s Anesthesia in Patients Undergoing Nasal Surgery\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remimazolam#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07265050
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901504-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07901504)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam vs Propofol for Moto
 r and Somatosensory Evoked Potentials in Spinal Tumor Surgery\nEstimated p
 rimary completion: January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07901504
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325227-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07325227)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Study of Remimazolam for Catarac
 t Surgery\nEstimated primary completion: 1 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07325227
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785557-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remimazolam: Phase na readout est. (NCT07785557)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam Versus Propofol for
  Early Recovery After Cytoreductive Surgery\nEstimated primary completion:
  March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazo
 lam#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07785557
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651956-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07651956)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam Versus Dexmedetomidi
 ne for Sedation During Neuraxial\nEstimated primary completion: May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07651956
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663877-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07663877)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remimazolam-Flumazenil Versus Se
 voflurane for Hysteroscopic Day Surgery\nEstimated primary completion: Jun
 e 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07663
 877
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725185-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Remimazolam: Phase na readout est. (NCT07725185)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Effects of Remimazolam on Posto
 perative Myocardial Injury\nEstimated primary completion: 1 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07725185
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07880548-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Remimazolam: Phase 3 readout est. (NCT07880548)
DESCRIPTION:Remimazolam\, phase 3.\nStudy: Remimazolam vs Propofol for Long
 -Term Sedation in Mechanically Ventilated ICU Patients\nEstimated primary 
 completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/remimazolam#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07880548
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836205-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07836205)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Brain Activity and Changes in Co
 nsciousness During General Anesthesia\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remimazola
 m#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 836205
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258356-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Remimazolam: Phase na readout est. (NCT06258356)
DESCRIPTION:Remimazolam\, phase na.\nStudy: Remimazolam in High Risk ERCP P
 atients\nEstimated primary completion: 31 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06258356
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194109-9526@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Remimazolam: Phase 4 readout est. (NCT07194109)
DESCRIPTION:Remimazolam\, phase 4.\nStudy: Remiazolam vs Propofol Total Int
 ravenous Anesthesia on Postoperative Neurodevelopment After General Anesth
 esia in Children\nEstimated primary completion: 1 October 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07194109
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
